Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Xavier Thomas. (2015) Novel approaches to pediatric leukemia treatment. Expert Review of Anticancer Therapy 15:7, pages 811-828.
Read now
Read now
Leonie K Ashman & Renate Griffith. (2013) Therapeutic targeting of c-KIT in cancer. Expert Opinion on Investigational Drugs 22:1, pages 103-115.
Read now
Read now
Felicetto Ferrara. (2012) New agents for acute myeloid leukemia: is it time for targeted therapies?. Expert Opinion on Investigational Drugs 21:2, pages 179-189.
Read now
Read now
Articles from other publishers (45)
Moon Nyeo Park. (2023) The Therapeutic Potential of a Strategy to Prevent Acute Myeloid Leukemia Stem Cell Reprogramming in Older Patients. International Journal of Molecular Sciences 24:15, pages 12037.
Crossref
Crossref
Jing Ye, Junhao Wu & Bo Liu. (2023) Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1878:3, pages 188866.
Crossref
Crossref
Lei Zhong, Yueshan Li, Liang Xiong, Wenjing Wang, Ming Wu, Ting Yuan, Wei Yang, Chenyu Tian, Zhuang Miao, Tianqi Wang & Shengyong Yang. (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Haleema Sadia Malik, Aishah Bilal, Rahim Ullah, Maheen Iqbal, Sardraz Khan, Ishtiaq Ahmed, Karsten Krohn, Rahman Shah Zaib Saleem, Hidayat Hussain & Amir Faisal. (2020) Natural and Semisynthetic Chalcones as Dual FLT3 and Microtubule Polymerization Inhibitors. Journal of Natural Products 83:10, pages 3111-3121.
Crossref
Crossref
Maoyu Liu, Xueming Ju, Jing Zou, Jianyou Shi & Guiqing Jia. (2020) Recent researches for dual Aurora target inhibitors in antitumor field. European Journal of Medicinal Chemistry 203, pages 112498.
Crossref
Crossref
Sameer P. Kawatkar, Bernard Barlaam, Paul Kemmitt, Iain Simpson, David Watson, Peng Wang, Scott Lamont, Qibin Su, Scott Boiko, Timothy Ikeda, Joe Patel, Andy Pike, Hannah Pollard, Jon Read, Ujjal Sarkar, Haiyun Wang, Quanshan Wen, Zhiyuan Yan, James E. Dowling, Hannah Dry & Scott D. Edmondson. (2020) Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase. Bioorganic & Medicinal Chemistry Letters 30:18, pages 127393.
Crossref
Crossref
Mohamed Elmeliegy, Jason Den Haese, Chetasi Talati, Meir Wetzler & William J. Jusko. (2020) Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia. Cancer Chemotherapy and Pharmacology 86:3, pages 325-337.
Crossref
Crossref
Andrew S. Moore, Amir Faisal, Grace W. Y. Mak, Farideh Miraki-MoudVassilios BavetsiasMelanie ValentiGary BoxAlbert HallsworthAlexis de Haven BrandonCristina P. R. XavierRandal Stronge, Andrew D. J. PearsonJulian BlaggFlorence I. Raynaud, Rajesh ChopraSuzanne A. EcclesDavid C. Taussig & Spiros Linardopoulos. (2020) Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736. Blood Advances 4:7, pages 1478-1491.
Crossref
Crossref
Francesca L. Wood, Sam Shepherd, Angela Hayes, Manjuan Liu, Katia Grira, Yi Mok, Butrus Atrash, Amir Faisal, Vassilios Bavetsias, Spiros Linardopoulos, Julian Blagg & Florence I. Raynaud. (2019) Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species. European Journal of Pharmaceutical Sciences 139, pages 104899.
Crossref
Crossref
Yu-Ting Chang, Daniela Hernandez, Salvador Alonso, Minling Gao, Meng Su, Gabriel Ghiaur, Mark J. Levis & Richard J. Jones. (2019) Role of CYP3A4 in bone marrow microenvironment–mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors. Blood Advances 3:6, pages 908-916.
Crossref
Crossref
Yanle Zhi, Baoquan Li, Chao Yao, Hongmei Li, Puzhou Chen, Jiyin Bao, Tianren Qin, Yue Wang, Tao Lu & Shuai Lu. (2018) Discovery of the selective and efficacious inhibitors of FLT3 mutations. European Journal of Medicinal Chemistry 155, pages 303-315.
Crossref
Crossref
Bettina Wingelhofer, Barbara Maurer, Elizabeth C. Heyes, Abbarna A. Cumaraswamy, Angelika Berger-Becvar, Elvin D. de Araujo, Anna Orlova, Patricia Freund, Frank Ruge, Jisung Park, Gary Tin, Siawash Ahmar, Charles-Hugues Lardeau, Irina Sadovnik, Dávid Bajusz, György Miklós Keserű, Florian Grebien, Stefan Kubicek, Peter Valent, Patrick T. Gunning & Richard Moriggl. (2018) Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia 32:5, pages 1135-1146.
Crossref
Crossref
Wojciech Czardybon, Renata Windak, Aniela Gołas, Michał Gałęzowski, Aleksandra Sabiniarz, Izabela Dolata, Magdalena Salwińska, Paweł Guzik, Magdalena Zawadzka, Ewelina Gabor-Worwa, Bożena Winnik, Małgorzata Żurawska, Ewa Kolasińska, Ewelina Wincza, Marta Bugaj, Monika Danielewicz, Eliza Majewska, Milena Mazan, Grzegorz Dubin, Monika Noyszewska-Kania, Ewa Jabłońska, Maciej Szydłowski, Tomasz Sewastianik, Bartosz Puła, Anna Szumera-Ciećkiewicz, Monika Prochorec-Sobieszek, Elżbieta Mądro, Ewa Lech-Marańda, Krzysztof Warzocha, Jerome Tamburini, Przemysław Juszczyński & Krzysztof Brzózka. (2018) A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget 9:24, pages 16917-16931.
Crossref
Crossref
Steven Knapper, Nigel RussellAmanda GilkesRobert K. HillsRosemary E. GaleJames D. CavenaghGail JonesLars KjeldsenMichael R. GrunwaldIan ThomasHeiko Konig, Mark J. Levis & Alan K. Burnett. (2017) A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129:9, pages 1143-1154.
Crossref
Crossref
Betty Lam, Yasuyoshi Arikawa, Joshua Cramlett, Qing Dong, Ron de Jong, Victoria Feher, Charles E. Grimshaw, Pamela J. Farrell, Isaac D. Hoffman, Andy Jennings, Benjamin Jones, Jennifer Matuszkiewicz, Joanne Miura, Hiroshi Miyake, Srinivasa Reddy Natala, Lihong Shi, Masashi Takahashi, Ewan Taylor, Corey Wyrick, Jason Yano, Jonathan Zalevsky & Zhe Nie. (2016) Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK). Bioorganic & Medicinal Chemistry Letters 26:24, pages 5947-5950.
Crossref
Crossref
Iris Z. UrasGina J. WalterRuth ScheicherFlorian BelluttiMichaela Prchal-MurphyAnca S. TiganPeter ValentFlorian H. HeidelStefan Kubicek, Claudia SchollStefan Fröhling & Veronika Sexl. (2016) Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood 127:23, pages 2890-2902.
Crossref
Crossref
Sorina Suarasan, Timea Simon, Sanda Boca, Ciprian Tomuleasa & Simion Astilean. (2016) Gelatin-coated Gold Nanoparticles as Carriers of FLT3 Inhibitors for Acute Myeloid Leukemia Treatment. Chemical Biology & Drug Design 87:6, pages 927-935.
Crossref
Crossref
Catherine C. Coombs, Martin S. Tallman & Ross L. Levine. (2015) Molecular therapy for acute myeloid leukaemia. Nature Reviews Clinical Oncology 13:5, pages 305-318.
Crossref
Crossref
Betul Tavil, Fatma Isgandarova, Turan Bayhan, Sule Unal, Baris Kuskonmaz, Fatma Gumruk & Mualla Cetin. (2016) Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia. Journal of Pediatric Hematology/Oncology 38:3, pages 240-242.
Crossref
Crossref
David Grimwade, Steven Knapper & Krzysztof Mrózek. 2016. Molecular Pathology in Clinical Practice. Molecular Pathology in Clinical Practice
527
559
.
Vassilios Bavetsias & Spiros Linardopoulos. (2015) Aurora Kinase Inhibitors: Current Status and Outlook. Frontiers in Oncology 5.
Crossref
Crossref
Chiung-Tong Chen, John T.-A. Hsu, Wen-Hsing Lin, Cheng-Tai Lu, Shih-Chieh Yen, Tsu Hsu, Yu-Ling Huang, Jen-Shin Song, Chun-Hwa Chen, Ling-Hui Chou, Kuei-Jung Yen, Ching-Ping Chen, Po-Chu Kuo, Chen-Lung Huang, H. Eugene Liu, Yu-Sheng Chao, Teng-Kuang Yeh & Weir-Torn Jiaang. (2015) Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations. European Journal of Medicinal Chemistry 100, pages 151-161.
Crossref
Crossref
Ni Zhu, Haowen Xiao, Li-Mengmeng Wang, Shan Fu, Chan Zhao & He Huang. (2015) Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies. Future Oncology 11:4, pages 659-673.
Crossref
Crossref
Ali J Mahdi, Eamon J Mahdi & Steven Knapper. (2015) Chemotherapeutic treatment of acute myeloid leukemia: incorporating the results of recent clinical trials. Clinical Investigation 5:1, pages 89-110.
Crossref
Crossref
Bernd B. Zeisig & Chi Wai Eric So. 2015. Chromosomal Translocations and Genome Rearrangements in Cancer. Chromosomal Translocations and Genome Rearrangements in Cancer
223
250
.
Guiyun Song, Benigno C. Valdez, Yang Li, Yan Liu, Richard E. Champlin & Borje S. Andersson. (2014) Synergistic Cytotoxicity of Sorafenib with Busulfan and Nucleoside Analogs in Human FMS-like Tyrosine Kinase 3 Internal Tandem Duplications–Positive Acute Myeloid Leukemia Cells. Biology of Blood and Marrow Transplantation 20:11, pages 1687-1695.
Crossref
Crossref
Deniz Peker, Vishwas Parekh, Ravikumar Paluri, Taylor Deal, Uma Borate, Antonio Di Stasi, Shuko Harada, Emmanuel Agosto Arroyo & Vishnu Reddy. (2014) Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: a single institution experience. International Journal of Hematology 100:5, pages 457-463.
Crossref
Crossref
Ajit Dhananjay Jagtap, Pei-Teh Chang, Jia-Rong Liu, Hsiao-Chun Wang, Nagendra B. Kondekar, Li-Jiuan Shen, Hsiang-Wen Tseng, Grace Shiahuy Chen & Ji-Wang Chern. (2014) Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia. European Journal of Medicinal Chemistry 85, pages 268-288.
Crossref
Crossref
Shuang Qu, Bin Liu, Xiaoling Guo, Hongshun Shi, Meifeng Zhou, Li Li, Shulan Yang, Xiuzhen Tong & Haihe Wang. (2014) Independent oncogenic and therapeutic significance of phosphatase PRL‐3 in FLT3‐ITD–negative acute myeloid leukemia. Cancer 120:14, pages 2130-2141.
Crossref
Crossref
Luca Szalontay & Aziza T. Shad. (2013) Pediatric Acute Myeloid Leukemia: How to Improve Outcome?. Current Pediatrics Reports 2:1, pages 26-37.
Crossref
Crossref
Andreas Brunschweiger & Jonathan Hall. 2013. Medicinal Chemistry Approaches to Personalized Medicine. Medicinal Chemistry Approaches to Personalized Medicine
343
364
.
A Caldarelli, J P Müller, M Paskowski-Rogacz, K Herrmann, R Bauer, S Koch, A K Heninger, D Krastev, L Ding, S Kasper, T Fischer, M Brodhun, F-D Böhmer & F Buchholz. (2013) A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling. Leukemia 27:12, pages 2301-2310.
Crossref
Crossref
Eric I. ZimmermanDavid C. TurnerJassada BuaboonnamShuiying HuShelley OrwickMichael S. RobertsLaura J. JankeAbhijit Ramachandran, Clinton F. StewartHiroto Inaba & Sharyn D. Baker. (2013) Crenolanib is active against models of drug-resistant FLT3-ITD−positive acute myeloid leukemia. Blood 122:22, pages 3607-3615.
Crossref
Crossref
Sharyn D. Baker, Eric I. Zimmerman, Yong-Dong Wang, Shelley Orwick, Douglas S. Zatechka, Jassada Buaboonnam, Geoffrey A. Neale, Scott R. Olsen, Eric J. Enemark, Sheila Shurtleff, Jeffrey E. Rubnitz, Charles G. Mullighan & Hiroto Inaba. (2013) Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia. Clinical Cancer Research 19:20, pages 5758-5768.
Crossref
Crossref
M. Miano, C. Micalizzi, M. Calvillo & C. Dufour. (2013) New targets in pediatric acute myeloid leukemia. Immunology Letters 155:1-2, pages 47-50.
Crossref
Crossref
Neil P. Shah, Moshe Talpaz, Michael W. N. Deininger, Michael J. Mauro, Ian W. Flinn, Dale Bixby, Stephanie Lustgarten, Joseph M. Gozgit, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Hagop Kantarjian & Jorge E. Cortes. (2013) Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. British Journal of Haematology 162:4, pages 548-552.
Crossref
Crossref
A S Moore, P R Kearns, S Knapper, A D J Pearson & C M Zwaan. (2013) Novel therapies for children with acute myeloid leukaemia. Leukemia 27:7, pages 1451-1460.
Crossref
Crossref
Qihui Li, Lei Huai, Cuiping Zhang, Cuicui Wang, Yujjao Jia, Yirui Chen, Pei Yu, Houcai Wang, Qing Rao, Min Wang & Jianxiang Wang. (2013) Icaritin induces AML cell apoptosis via the MAPK/ERK and PI3K/AKT signal pathways. International Journal of Hematology 97:5, pages 617-623.
Crossref
Crossref
A Y H Leung, C-H Man & Y-L Kwong. (2012) FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. Leukemia 27:2, pages 260-268.
Crossref
Crossref
Felicetto Ferrara & Charles A Schiffer. (2013) Acute myeloid leukaemia in adults. The Lancet 381:9865, pages 484-495.
Crossref
Crossref
Lucy A. Godley. (2012) A drug that stops traffic at the nuclear border. Blood 120:9, pages 1759-1760.
Crossref
Crossref
A S Moore, A Faisal, D Gonzalez de Castro, V Bavetsias, C Sun, B Atrash, M Valenti, A de Haven Brandon, S Avery, D Mair, F Mirabella, J Swansbury, A D J Pearson, P Workman, J Blagg, F I Raynaud, S A Eccles & S Linardopoulos. (2012) Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia 26:7, pages 1462-1470.
Crossref
Crossref
Elspeth M. Beauchamp & Leonidas C. Platanias. (2012) BH3 mimetics and multi-kinase inhibition in AML. Blood 119:25, pages 5947-5948.
Crossref
Crossref
Michael S MathisenFarhad Ravandi. (2012) Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial. Future Oncology 8:4, pages 351-357.
Crossref
Crossref
Andreas Brunschweiger & Jonathan Hall. (2012) A Decade of the Human Genome Sequence-How Does the Medicinal Chemist Benefit?. ChemMedChem 7:2, pages 194-203.
Crossref
Crossref